Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

Enumeral Biomedical Holdings, Inc. (the Company) may use two
slide presentations, in whole or in part, from time to time in
presentations to potential partners, investors, analysts and
others. Copies of the slide presentations are furnished as
Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K
and incorporated by reference herein. Copies of the slide
presentations are also available on the Companys website at
www.enumeral.com.

The information in this Item 7.01 of this Current Report on Form
8-K and in the accompanying Exhibit 99.1 and Exhibit 99.2 shall
not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section or Sections 11 and 12(a)(2) of
the Securities Act of 1933, as amended. The information contained
in this Item 7.01 of this Current Report on Form 8-K and in the
accompanying Exhibit 99.1 and Exhibit 99.2 shall not be
incorporated by reference into any filing with the U.S.
Securities and Exchange Commission made by the Company, whether
made before or after the date hereof, regardless of any general
incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

About Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL)

Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company focused on discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. The Company utilizes a platform technology that facilitates the resolution measurement of immune cell function within small tissue biopsy samples. Its initial focus is on the development of a pipeline of monoclonal antibody drugs targeting established and immuno-modulatory receptors. Its platform technology is a microwell array technology that detects secreted molecules (such as antibodies and cytokines) and cell surface markers at the level of single, live cells and enables recovery of single, live cells of interest. Its program involves antibodies against the Programmed Cell Death receptor, commonly known as (PD-1). In addition to its PD-1 antibody program, it is developing antibody drug candidates for a number of immunomodulatory protein targets, including TIM-3, LAG-3, OX40, TIGIT and VISTA.

Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) Recent Trading Information

Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) closed its last trading session at 0.150 with shares trading hands.